Newbury Pharmaceuticals AB (publ) (STO:NEWBRY)
Sweden · Delayed Price · Currency is SEK 1.105
-0.160 (-12.65%)
Jan 21, 2026, 1:06 PM CET
STO:NEWBRY Revenue
Newbury Pharmaceuticals AB had revenue of 12.21M SEK in the quarter ending November 30, 2025, with 86.71% growth. This brings the company's revenue in the last twelve months to 36.23M, up 9.15% year-over-year. In the fiscal year ending August 31, 2025, Newbury Pharmaceuticals AB had annual revenue of 31.57M, down -14.27%.
Revenue (ttm)
36.23M
Revenue Growth
+9.15%
P/S Ratio
1.06
Revenue / Employee
6.04M
Employees
6
Market Cap
38.45M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 31.57M | -5.26M | -14.27% |
| Aug 31, 2024 | 36.83M | 26.56M | 258.75% |
| Aug 31, 2023 | 10.27M | 4.75M | 86.11% |
| Aug 31, 2022 | 5.52M | 2.43M | 78.73% |
| Aug 31, 2021 | 3.09M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Getinge AB | 35.85B |
| Swedish Orphan Biovitrum AB | 27.85B |
| Medicover AB | 25.67B |
| Elekta AB | 17.57B |
| Asker Healthcare Group AB | 16.41B |
| AddLife AB | 10.53B |
| Nolato AB | 9.57B |
| Vitrolife AB | 3.51B |